Literature DB >> 18693057

[Use of PET for staging, treatment evaluation, and follow-up in esophageal cancers].

E Touboul1, F Huguet, J-N Talbot.   

Abstract

FDG-(18F) PET can now be usually included in the treatment strategy of esophageal cancers for the pretreatment staging in operable tumours or for the diagnosis of recurrence. PET is also a good tool in conformal radiation therapy for improving the target coverage to treat the metabolic target volume or the biological target volume. Furthermore, PET seems to be interesting for evaluation of tumour response and could modify the treatment strategy after neoadjuvant chemotherapy or concurrent chemotherapy and radiation therapy. New radiotracers could allow advances in biological and molecular tumour delineation and contribute to change in treatment strategy based on functional and biological imaging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18693057     DOI: 10.1016/j.canrad.2008.07.001

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.

Authors:  Charles Lemarignier; Frédéric Di Fiore; Charline Marre; Sébastien Hapdey; Romain Modzelewski; Pierrick Gouel; Pierre Michel; Bernard Dubray; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-19       Impact factor: 9.236

2.  Efficacy of 4'-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study.

Authors:  Masatoshi Hotta; Ryogo Minamimoto; Kazuhiko Yamada; Kyoko Nohara; Daisuke Soma; Kazuhiko Nakajima; Jun Toyohara; Kei Takase
Journal:  EJNMMI Res       Date:  2019-01-30       Impact factor: 3.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.